A registered study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · PREVENTION · TRIPLE
- Evidence population
- Human clinical study registration
- Participants
- 220
- Population
- ALL · 35 Years to 50 Years
- Duration
- 2023-10-31 to 2027-01-30
- Intervention
- Treatment; Placebo
- Comparator
- Placebo
- Outcomes measured
- Blood pressure — Baseline, Month 3 and Month 6; Changes in Advanced Glycation End Products (AGEs) — Baseline, Month 3, and Month 6; Changes in Protein Carbonyl — Baseline, Month 3, and Month 6; Change in Malondialdehyde (MDA) — Baseline, Month 3, and Month 6; Change in DNA Damage — Baseline, Month 3, and Month 6; Body Composition assessment — Baseline, Month 3, and Month 6; Food intake questionnaire — Baseline, Month 3, and Month 6; Changes in SASP Gene expression — Baseline, Month 3, and Month 6; Change in SASP Protein expression — Baseline, Month 3, and Month 6; Change in Tumor Necrosis Factor-Alpha (TNF-α) — Baseline, Month 3, and Month 6; Change in Inteleukin-6 (IL-6) — Baseline, Month 3, and Month 6; Change in ATP production — Baseline, Month 3, and Month 6; Change in Mitochondrial Complex V Enzyme Activity — Baseline, Month 3, and Month 6; Change in Mitochondrial Membrane Potential — Baseline, Month 3, and Month 6; Change in Plasma Alpha-Tocotrienol Concentration — Baseline, Month 3, and Month 6; Change in Plasma Gamma- Tocotrienol Concentration — Baseline, Month 3, and Month 6; Change in Total Plasma Tocotrienol Concentration — Baseline, Month 3, and Month 6; Muscle mass — Baseline and Month 6; Fat mass — Baseline and Month 6; Bone mineral content (BMC) — Baseline and Month 6
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Senolytics · 100%Title contains controlled term: senolytic. Abstract contains controlled term: senolytic, cellular senescence. Abstract supplies longevity context: aging, senescence. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.